The U.S. Food and Drug Administration (FDA) is planning to make recommendations on how to regulate the use of popular cannabis compound CBD in food and supplements, the Wall Street Journal reported on Tuesday, citing agency officials.
Cannabis products, excluding Jazz Pharmaceuticals PLC's
Epidiolex, are illegal at the federal level in the United States, although some states allow their use. The agency wants to know if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility, Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, told WSJ.
When asked for comment, the FDA referred Reuters to a statement from last year which said the agency was taking steps to improve regulatory pathways for the lawful marketing of appropriate cannabis and cannabis-derived products.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
WSJ News Exclusive | FDA, Concerned About Safety, Explores Regulating CBD in Foods, SupplementsThe agency is studying whether cannabis-derived ingredients are safe in food and supplements and aims to reveal its oversight plans in the coming months.
Les mer »
U.S. FDA weighs regulating cannabis compound CBD in food, supplements - WSJAfter weighing the evidence on the compound's safety, the FDA will decide within months how to regulate legal cannabis and whether that will require new agency rules or new legislation from Congress, according to the report. Cannabis products, excluding Jazz Pharmaceuticals PLC's Epidiolex, are illegal at the federal level in the United States, although some states allow their use. The agency wants to know if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility, Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, told WSJ.
Les mer »
U.S. FDA weighs regulations on cannabis products in food and diet supplementsFDA officials tell the Wall Street Journal that safety concerns around CBD may cause the agency to publish its first guidelines on cannabis-derived products.
Les mer »
Blood pressure tablets recalled over potential cancer risk, FDA announcesPatients who are on the medication don’t need to stop taking it immediately, but are advised to discuss an alternative treatment with their healthcare provider.
Les mer »
Blood pressure tablets recalled over potential cancer risk, FDA announcesThe FDA announced the second recall in months of blood-pressure medication over an elevated cancer risk. This time Quinapril tablets are being pulled.
Les mer »
FDA Fast-Tracks Overdose Drug Naloxone for Use Without PrescriptionA pharmaceutical nonprofit was granted priority review from the FDA to make an inexpensive overdose-reversal drug for use without a prescription
Les mer »